magrolimab in tp53 mutated aml and mds
Published 3 years ago • 298 plays • Length 2:50Download video MP4
Download video MP3
Similar videos
-
2:24
the challenges of treating tp53-mutated aml and mds
-
1:57
tolerability and efficacy of magrolimab plus azacitidine in tp53-mutated aml patients
-
1:40
outcomes of allohsct in tp53-mutated aml and mds
-
0:41
promising agents in aml: menin inhibitors & magrolimab in tp53-mutated aml
-
1:59
depth of molecular response in patients with tp53m mds & aml treated with magrolimab and azacitidine
-
2:43
magrolimab azacitidine in tp53-mutant aml
-
2:42
forty seven magrolimab
-
11:06
how could new treatment options improve outcomes in flt3-mutated aml?
-
4:49
sample probe maintenance
-
3:39
the association between prior exposure to lenalidomide and tp53-mutated aml/mds
-
0:44
predictors of poor response to azacitidine, venetoclax, and magrolimab in tp53-mutated aml
-
3:22
is tp53-mutated high-risk mds the same disease as tp53-mutated aml?
-
5:16
an analysis of tp53 mutation in aml and hr-mds
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
3:00
apr-246 in tp53 mutated mds and aml
-
7:37
magrolimab in tp53-mutated aml and mds: what are the latest updates from eha2022?
-
2:26
enhance-2: phase iii study of magrolimab plus azacitidine in untreated tp53-mutant aml
-
1:26
updates in the treatment landscape of p53-mutated aml/mds
-
2:23
improving treatment for patients with tp53-mutated myeloid malignancies
-
3:19
an overview of novel treatment approaches in tp53-mutated aml
-
0:58
options available to patients with tp53-mutated mds beyond stem cell transplantation
-
1:24
antibodies for the treatment of mds: magrolimab & sabatolimab